Dr. Chujie Bai 白楚杰
Chief Physician, Lecturer
Department of Bone and Soft Tissue Tumors, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Standardized treatment of bone and soft tissue tumors, chemotherapy and limb-salvage therapy for sarcomas and osteosarcomas, reconstruction of soft tissue defects after sarcoma surgery, orthopedic reconstruction for joint and spinal fracture deformities, and surgical treatment of bone metastases.
Dr. Bai holds a PhD from Soochow University Medical College and completed one year of advanced training at Hessing Clinic Orthopedic Specialist Center in Augsburg, Germany. Since 2007, Dr. Bai has worked in the Department of Bone and Soft Tissue Tumors at Peking University Cancer Hospital as a Chief Physician and has published multiple articles in core journals and SCI-indexed publications.
Professional roles
- Secretary, Sarcoma Professional Committee, Beijing Anti-Cancer Association
- Member, Science Popularization Professional Committee, Beijing Anti-Cancer Association
- Member, Head and Neck Professional Committee, National Tumor Minimally Invasive Industry Technology Innovation Strategic Alliance
- Secretary-General, Tumor Multidisciplinary Diagnosis and Treatment Expert Committee, Beijing Medical Reward Foundation
Name order: in Chinese the family name comes first (Bai Chujie). Papers usually list the name as Chujie Bai or Bai C.
Selected publications
25 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- Anticancer Drugs, 2024 (first author): Targeting MCM2 activates cancer-associated fibroblasts-like phenotype and affects chemo-resistance of liposarcoma cells against doxorubicin. PubMed 39109389
- J Cancer Res Clin Oncol, 2022 (first author): A novel TMTC2-NTRK3 fusion in undifferentiated high-grade pleomorphic sarcoma. PubMed 35933643
- Neoplasma, 2022 (first author): SNHG9/miR-214-5p/SOX4 feedback loop regulates osteosarcoma progression. PubMed 36004648
- Am J Transl Res, 2022 (first author): Correlation between pathological features and protein expressions of TfR1, VEGF and MMP-9 in patients with osteosarcoma. PubMed 35958455
- J Exp Clin Cancer Res, 2015 (first author): Associations of chemo- and radio-resistant phenotypes with the gap junction, adhesion and extracellular matrix in a three-dimensional culture model of soft sarcoma. PubMed 26055407
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion